ValueAct's Jeff Ubben (Trades, Portfolio) sat down for a lengthy interview with CNBC.
In the interview he covered the fact that he is finding few high quality companies at attractive prices, why he supports Valeant Pharma (VRX, Financial) and why he thinks oil could be headed back to $100.
Over the past 12 months Ubben has purchased only one high quality business. He identifies which one in the interview below:
